GlassScriptPhysician profile
Peter David Reaven
NPI 1316977721
$1,905.04
in general payments reported to CMS, 2019-2025
11 companies · $98.94 in 2025
The $98.94 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $1,115 · 2021: $215 · 2022: $236 · 2025: $98.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $1,040.00 | 2020 | |
| Novo Nordisk INC | $368.23 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.13 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $88.20 | 2022 | |
| Esperion Therapeutics, INC. | $75.00 | 2020 | |
| Amarin Pharma, INC. | $59.25 | 2019 | |
| Corcept Therapeutics | $50.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.26 | 2019 | |
| Dexcom, INC. | $12.97 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Reaven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.